“Expected Spesolimab Plasma Exposure Following Intravenous and Subcutaneous Dosing in Patients With Generalized Pustular Psoriasis”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s359. Accessed May 19, 2025. https://skin.dermsquared.com/skin/article/view/2655.